课题基金 / 基金详情

项目摘要

项目成果

RICHARD Frederick AMBINDER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
For our next five-year plan we have aligned ourselves to the goals of discovering, developing, and translating molecular imaging technologies to understand, detect, and treat cancer. Our efforts and expertise will be applied collectively and synergistically for this purpose. By engaging and integrating clinical oncologists, radiologists, pathologists, and surgeons within every aspect of the program, we have ensured the translation of our most exciting discoveries to improve treatment outcome in patients. This unique collection of highly interactive research-scientists and clinician-scientists within an environment rich in multi-modality imaging expertise and equipment is necessary to make the catapulting advances and discoveries that are essential to find effective treatments for cancer. The JHU ICMIC Program consists of four research components, four developmental projects, four resources, and a career development component. The four research components have a major emphasis on clinical translation and cover different aspects of understanding, detecting, and treating cancer. These are (i) theranostic imaging of metastatic prostate cancer, (ii) BETR (bortezomib-induced enzyme targeted radiation) theranostics for Kaposi's sarcoma (KS), (iii) exchange transfer-based molecular MRI in oncology and (iv) molecular imaging of the extracellular matrix (ECM) and its avenues for metastasis. Similarly, the four developmental projects cover a range of topics, such as (i) force propagation in melanoma cancer progression, (ii) imaging peri-tumoral stromal depletion as a surrogate for treatment efficacy in pancreatic cancer, (iii) lung-specific Twist mediated epithelial to mesenchymal transition (EMT) in lung premetastatic niche, and (iv) blockade of the hypoxia inducible factor (HIF)-1 pathway in bone metastasis from renal cancer. We have structured four specialized resources (the Administrative Resource, the Molecular Oncology Resource, the Imaging and Probes Resource, and the Biostatistics Resource) to provide the infrastructure to support the current and future projects of the JHU ICMIC. The Career Development Component is structured with the purpose of creating independently funded investigators who will, in the future, become leaders in the field.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva
  • 批准号:
    10755171
  • 项目类别:
  • 资助金额:
    $71.37万
  • 财政年份:
    2023
  • 负责人:
    RICHARD Frederick AMBINDER
  • 依托单位:
Clonal Immunoglobulin DNA and Lymphoma Diagnosis
  • 批准号:
    9927306
  • 项目类别:
  • 资助金额:
    $17.51万
  • 财政年份:
    2020
  • 负责人:
    RICHARD Frederick AMBINDER
  • 依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
  • 批准号:
    10377440
  • 项目类别:
  • 资助金额:
    $81.44万
  • 财政年份:
    2020
  • 负责人:
    RICHARD Frederick AMBINDER
  • 依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
  • 批准号:
    10824451
  • 项目类别:
  • 资助金额:
    $10.44万
  • 财政年份:
    2020
  • 负责人:
    RICHARD Frederick AMBINDER
  • 依托单位:
国内基金
海外基金
bortezomib抑制寨卡病毒复制的分子机制研究
蛋白酶体抑制剂硼替佐米(Bortezomib)对血管渗漏的改善及机制研究
  • 批准号:
    81772041
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2017
  • 负责人:
    汤耀卿
  • 依托单位:
蛋白酶体抑制剂Bortezomib对肺动脉平滑肌细胞钙离子通路的作用研究
  • 批准号:
    81460011
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    40.0万元
  • 批准年份:
    2014
  • 负责人:
    徐磊
  • 依托单位: